BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Forodesine: Interim Phase II data

Interim data from an ongoing, open-label, U.S. and Australian Phase II trial in 25 patients who had failed >=1 prior treatment regimen showed that 200 mg twice-daily oral forodesine produced 3 partial responses. BioCryst previously...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >